Aphria adds to planned portfolio of vapes & concentrates with PAX Labs agreement
Solei, RIFF and Aphria medical cannabis to be available for the PAX Era device and platform
LEAMINGTON, ON, June 7, 2019 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced an agreement with San Francisco-based PAX Labs, Inc. ("PAX"), a leader in the design and development of premium cannabis vaporization devices, that will enable Aphria to provide premium cannabis extracts in pods designed for use with PAX's innovative Era device and platform. The Company plans to introduce PAX pods for both adult-use consumers and medical patients, pending anticipated changes to the Cannabis Act to permit the sale of cannabis extracts for vaporization.
